PMID- 37892698 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231030 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 12 IP - 20 DP - 2023 Oct 16 TI - Biomarkers for Assessing Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus on Sodium-Glucose Cotransporter 2 Inhibitor Therapy. LID - 10.3390/jcm12206561 [doi] LID - 6561 AB - In the current modern era of unhealthy lifestyles, non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease and has become a serious global health problem. To date, there is no approved pharmacotherapy for the treatment of NAFLD, and necessary lifestyle changes such as weight loss, diet, and exercise are usually not sufficient to manage this disease. Patients with type 2 diabetes mellitus (T2DM) have a significantly higher risk of developing NAFLD and vice versa. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are antidiabetic agents that have recently been approved for two other indications: chronic kidney disease and heart failure in diabetics and non-diabetics. They are also emerging as promising new agents for NAFLD treatment, as they have shown beneficial effects on hepatic inflammation, steatosis, and fibrosis. Studies in animals have reported favorable effects of SGLT2 inhibitors, and studies in patients also found positive effects on body mass index (BMI), insulin resistance, glucose levels, liver enzymes, apoptosis, and transcription factors. There are some theories regarding how SGLT2 inhibitors affect the liver, but the exact mechanism is not yet fully understood. Therefore, biomarkers to evaluate underlying mechanisms of action of SGLT2 inhibitors on the liver have now been scrutinized to assess their potential as a future in-label therapy for NAFLD. In addition, finding suitable non-invasive biomarkers could be helpful in clinical practice for the early detection of NAFLD in patients. This is crucial for a positive disease outcome. The aim of this review is to provide an overview of the most recent findings on the effects of SGLT2 inhibitors on NAFLD biomarkers and the potential of SGLT2 inhibitors to successfully treat NAFLD. FAU - Khaznadar, Farah AU - Khaznadar F AD - Faculty of Dental Medicine and Health Osijek, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia. AD - Faculty of Medicine Osijek, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia. FAU - Petrovic, Ana AU - Petrovic A AD - Faculty of Dental Medicine and Health Osijek, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia. FAU - Khaznadar, Omar AU - Khaznadar O AD - Department of Radiology, "Dr. Juraj Njavro" National Memorial Hospital Vukovar, 32000 Vukovar, Croatia. FAU - Roguljic, Hrvoje AU - Roguljic H AD - Faculty of Dental Medicine and Health Osijek, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia. AD - Faculty of Medicine Osijek, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia. AD - Clinical Hospital Center, 31000 Osijek, Croatia. FAU - Bojanic, Kristina AU - Bojanic K AD - Faculty of Dental Medicine and Health Osijek, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia. AD - Faculty of Medicine Osijek, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia. AD - Health Center Osijek-Baranja County, 31000 Osijek, Croatia. FAU - Kuna Roguljic, Lucija AU - Kuna Roguljic L AD - Faculty of Dental Medicine and Health Osijek, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia. FAU - Siber, Stjepan AU - Siber S AD - Faculty of Dental Medicine and Health Osijek, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia. FAU - Smolic, Robert AU - Smolic R AD - Faculty of Dental Medicine and Health Osijek, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia. FAU - Bilic-Curcic, Ines AU - Bilic-Curcic I AUID- ORCID: 0000-0002-8861-5987 AD - Faculty of Medicine Osijek, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia. AD - Clinical Hospital Center, 31000 Osijek, Croatia. FAU - Wu, George Y AU - Wu GY AD - Department of Medicine, Division of Gastrenterology/Hepatology, University of Connecticut Health Center, Farmington, CT 06030, USA. FAU - Smolic, Martina AU - Smolic M AUID- ORCID: 0000-0002-6867-826X AD - Faculty of Dental Medicine and Health Osijek, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia. LA - eng GR - IP14-MEFOS-2022 (M.S.)/Croatian Ministry of Science and Education/ PT - Journal Article PT - Review DEP - 20231016 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC10607797 OTO - NOTNLM OT - NAFLD OT - SGLT2 inhibitors OT - biomarkers OT - diabetes mellitus type 2 COIS- The authors declare no conflict of interest. EDAT- 2023/10/28 11:47 MHDA- 2023/10/28 11:48 PMCR- 2023/10/16 CRDT- 2023/10/28 01:05 PHST- 2023/09/15 00:00 [received] PHST- 2023/10/11 00:00 [revised] PHST- 2023/10/13 00:00 [accepted] PHST- 2023/10/28 11:48 [medline] PHST- 2023/10/28 11:47 [pubmed] PHST- 2023/10/28 01:05 [entrez] PHST- 2023/10/16 00:00 [pmc-release] AID - jcm12206561 [pii] AID - jcm-12-06561 [pii] AID - 10.3390/jcm12206561 [doi] PST - epublish SO - J Clin Med. 2023 Oct 16;12(20):6561. doi: 10.3390/jcm12206561.